Belatacept for kidney transplant recipients.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cochrane Database of Systematic Reviews

• Publication date

  2014-11-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/14651858.CD010699.pub2PMID 25416857PMCID PMC6486198
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Belatacept for kidney transplant recipients

  2015cited by this paper
• Beneficial Effect of Belatacept on Health-Related Quality of Life and Perceived Side Effects: Results From the BENEFIT and BENEFIT-EXT Trials

  2014cited by this paper
• Belatacept for kidney transplant recipients.

  2014cited by this paper
• Outcomes at 3 Years in EBV+ European Subpopulations From BENEFIT and BENEFIT-EXT.: Abstract# A198

  2014cited by this paper
• Outcomes at 3-Years in EBV+ Recipients of UNOS Criteria ECD Kidneys From a Randomized Trial (BENEFIT-EXT) Comparing Belatacept vs Cyclosporine.: Abstract# A202

  2014cited by this paper
• Outcomes at 4 Years in a Randomized Trial Evaluating Belatacept-Based Regimens With Simultaneous CNI and Steroid-Avoidance in Kidney Transplant.: Abstract# 2162

  2014cited by this paper
• Renal Function at 4 Years in a Phase 2 Randomized Trial Evaluating Belatacept-Based Regimens With Simultaneous Calcineurin Inhibitor and Corticosteroid Avoidance in Kidney Transplant Recipients.: Abstract# 2157

  2014cited by this paper
• Final Results From the Long-Term Extension (LTE) of the Belatacept Phase 2 Study in Kidney Transplantation.: Abstract# 2164

  2014cited by this paper
• Evaluation of Donor-Specific Antibodies Through 5 Years With Belatacept in BENEFIT and BENEFIT-EXT.: Abstract# 2163

  2014cited by this paper
• Consistency and Completeness of Reported Outcomes in Randomized Trials of Primary Immunosuppression in Kidney Transplantation

  2013cited by this paper
• Belatacept and Sirolimus Prolong Nonhuman Primate Islet Allograft Survival: Adverse Consequences of Concomitant Alefacept Therapy

  2013cited by this paper
• Long‐Term Exposure to Belatacept in Recipients of Extended Criteria Donor Kidneys

  2013cited by this paper
• Immunosuppressive properties of a series of novel inhibitors of the monocarboxylate transporter MCT‐1

  2013cited by this paper
• Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study

  2013cited by this paper
• The Uppsala Experience of Switching from Cni:s to Belatacept after Kidney Transplantation

  2013cited by this paper
• Vaccination in Solid Organ Transplantation

  2013cited by this paper
• Improvement in renal function in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: 2‐year results from the long‐term extension of a phase II study

  2012cited by this paper
• 10 Yearsʼ Experience with Belatacept (Nulojix®): 450

  2012cited by this paper
• Comparative Survival and Economic Benefits of Deceased Donor Kidney Transplantation and Dialysis in People with Varying Ages and Co-Morbidities

  2012cited by this paper
• Three‐Year Outcomes From BENEFIT‐EXT: A Phase III Study of Belatacept Versus Cyclosporine in Recipients of Extended Criteria Donor Kidneys

  2012cited by this paper
• Three‐Year Outcomes from BENEFIT, a Randomized, Active‐Controlled, Parallel‐Group Study in Adult Kidney Transplant Recipients

  2012cited by this paper
• The new BMJ policy on sharing data from drug and device trials

  2012cited by this paper
• Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT): 1853

  2012cited by this paper
• Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up‐regulation and p16INK4α senescence protein down‐regulation in patients treated with belatacept compared to cyclosporin A

  2012cited by this paper
• Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

  2011cited by this paper
• INTERSTITIAL PNEUMONITIS CAUSED BY EVEROLIMUS; A CASE CONTROL STUDY

  2011cited by this paper
• Single graft loss in dual renal transplant recipients: impact of graft placement on recipient outcomes

  2011cited by this paper
• Immunosuppression with Belatacept‐Based, Corticosteroid‐Avoiding Regimens in De Novo Kidney Transplant Recipients

  2011cited by this paper
• Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.

  2011cited by this paper
• The ORION Study: Comparison of Two Sirolimus‐Based Regimens versus Tacrolimus and Mycophenolate Mofetil in Renal Allograft Recipients

  2011cited by this paper
• Desensitization for renal transplantation: depletion of donor‐specific anti‐HLA antibodies, preservation of memory antibodies, and clinical risks

  2011cited by this paper
• Cytomegalovirus Latency Promotes Cardiac Lymphoid Neogenesis and Accelerated Allograft Rejection in CMV Naïve Recipients

  2011cited by this paper
• Five-Year Safety and Efficacy of Belatacept in Renal Transplantation

  2011cited by this paper
• T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade.

  2011cited by this paper
• Belatacept-Based Regimens Are Associated With Improved Cardiovascular and Metabolic Risk Factors Compared With Cyclosporine in Kidney Transplant Recipients (BENEFIT and BENEFIT-EXT Studies)

  2011cited by this paper
• BELATACEPT VS CYCLOSPORINE IN ECD KIDNEY TRANSPLANTS: TWO-YEAR OUTCOMES FROM THE BENEFIT-EXT STUDY: 1394

  2010cited by this paper
• SWITCH FROM A CNI- TO A BELATACEPT-BASED IMMUNOSUPPRESSIVE REGIMEN IN KIDNEY TRANSPLANT RECIPIENTS IS SAFE AND RESULTS IN BETTER RENAL FUNCTION: 12 MONTH RESULTS FROM A PHASE II STUDY: 1446

  2010cited by this paper
• OUTCOMES AS A FUNCTION OF DONOR CRITERIA FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT-EXT): 1773

  2010cited by this paper
• BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANT RECIPIENTS: TWO-YEAR OUTCOMES FROM THE BENEFIT STUDY: 1374

  2010cited by this paper
• Use of kidney function end points in kidney transplant trials: a systematic review.

  2010cited by this paper
• A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

  2010cited by this paper
• Baseline Donor‐Specific Antibody Levels and Outcomes in Positive Crossmatch Kidney Transplantation

  2010cited by this paper
• Belatacept-Based Regimens Versus a Cyclosporine A-Based Regimen in Kidney Transplant Recipients: 2-Year Results From the BENEFIT and BENEFIT-EXT Studies

  2010cited by this paper
• HIGH EXPRESSION OF THE PRO-RENIN RECEPTOR IN ALDOSTERONE PRODUCING ADENOMA CAUSING HUMAN PRIMARY ALDOSTERONISM: 4D.02

  2010cited by this paper
• A Phase III Study of Belatacept‐based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study)

  2010cited by this paper
• An Integrated Safety Profile Analysis of Belatacept in Kidney Transplant Recipients

  2010cited by this paper
• Steroids in Pediatric Kidney Transplantation: A Balancing Act in Progress

  2010cited by this paper
• Five-year safety and efficacy of belatacept in renal transplantation.

  2010cited by this paper
• High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment.

  2010cited by this paper
• SAFETY PROFILE OF BELATACEPT IN KIDNEY TRANSPLANT RECIPIENTS FROM A POOLED ANALYSIS OF PHASE II AND PHASE III STUDIES: 1417

  2010cited by this paper
• BENEFIT-RISK PROFILE OF THE BELATACEPT LI REGIMEN AT 2 YEARS IN EBV(+) KIDNEY TRANSPLANT RECIPIENTS: 3370

  2010cited by this paper
• IMMUNOSUPPRESSION WITH BELATACEPT-BASED, CNI-AVOIDING AND STEROID-AVOIDING REGIMENS VS A TACROLIMUS-BASED, STEROID-AVOIDING REGIMEN IN KIDNEY TRANSPLANT PATIENTS: RESULTS OF A 1-YEAR, RANDOMIZED STUDY: 1436

  2010cited by this paper
• OUTCOMES AS A FUNCTION OF DONOR:RECIPIENT CHARACTERISTICS FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT): 2857

  2010cited by this paper
• Allograft‐Specific Cytokine Profiles Associate with Clinical Outcome After Islet Cell Transplantation

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

  2009cited by this paper
• Tuesday, 1 September 2009 ‐ Parallel Sessions 19‐36

  2009cited by this paper
• Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation

  2009cited by this paper
• De Novo Donor‐Specific Antibody at the Time of Kidney Transplant Biopsy Associates with Microvascular Pathology and Late Graft Failure

  2009cited by this paper
• The alphabet soup of kidney transplantation: SCD, DCD, ECD--fundamentals for the practicing nephrologist.

  2009cited by this paper
• Assessment of Belatacept-Mediated Costimulation Blockade Through Evaluation of CD80/86-Receptor Saturation

  2009cited by this paper
• Wednesday, 2 September 2009 ‐ Parallel Sessions 37‐42

  2009cited by this paper
• Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

  2009cited by this paper
• Interlaboratory Comparison of Cytomegalovirus Viral Load Assays

  2009cited by this paper
• Urological complications and their impact on survival after kidney transplantation from deceased cardiac death donors

  2009cited by this paper
• Managing Cancer Risk and Decision Making After Kidney Transplantation

  2008cited by this paper
• Reduced exposure to calcineurin inhibitors in renal transplantation.

  2008cited by this paper
• The Effect of Costimulatory and Interleukin 2 Receptor Blockade on Regulatory T Cells in Renal Transplantation

  2008cited by this paper
• LONG-TERM SAFETY OF BELATACEPT: 6 YEAR RESULTS OF A PHASE II STUDY: 621

  2008cited by this paper
• The role of indoleamine 2,3‐dioxygenase in transplantation

  2007cited by this paper
• Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade.

  2007cited by this paper
• Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus Tacrolimus

  2007cited by this paper
• C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients

  2005cited by this paper
• Early cyclosporine withdrawal from a sirolimus‐based regimen results in better renal allograft survival and renal function at 48 months after transplantation

  2005cited by this paper
• Belatacept (LEA29Y) as part of a CNI-free regimen in recipients of renal allografts with higher risk of poor long-term function and graft loss: Comparison with cyclosporine A

  2005cited by this paper
• Malignancy after Transplantation

  2005cited by this paper
• Risk Factors for Cardiovascular Events After Successful Renal Transplantation

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• A Randomized Controlled Trial of Late Conversion from CNI‐Based to Sirolimus‐Based Immunosuppression Following Renal Transplantation

  2005cited by this paper
• Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients.

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• New immunosuppressant FK778 shows efficacy in renal transplantation

  2004cited by this paper
• Lack of Improvement in Renal Allograft Survival Despite a Marked Decrease in Acute Rejection Rates Over the Most Recent Era

  2004cited by this paper
• CO-STIMULATION BLOCKADE WITH LEA29Y IN A CALCINEURIN INHIBITOR FREE MAINTENANCE REGIMEN IN RENAL TRANSPLANT: 6-MONTH EFFICACY AND SAFETY

  2004cited by this paper
• CO-STIMULATION BLOCKADE WITH LEA29Y IN RENAL TRANSPLANT: IMPROVED RENAL FUNCTION AND CV/METABOLIC PROFILE AT 6 MONTHS COMPARED WITH CYCLOSPORINE

  2004cited by this paper
• Calcineurin Inhibitor Nephrotoxicity: Longitudinal Assessment by Protocol Histology

  2004cited by this paper
• Improving the quality of reporting in randomised controlled trials.

  2004cited by this paper
• The natural history of chronic allograft nephropathy.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

  1999cited by this paper
• The role of T-cell costimulatory activation pathways in transplant rejection.

  1998cited by this paper
• Improving the quality of reporting of randomized controlled trials. The CONSORT statement.

  1996cited by this paper
• Recombinant fusion proteins

  1985cited by this paper

• Co-Stimulatory Blockade and Infectious Risk in Solid Organ Transplantation.

  2026cites this paper
• Systematic review and meta-analysis of belatacept versus calcineurin inhibitors on risk of post-transplant diabetes mellitus in kidney transplant recipients.

  2026cites this paper
• Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation

  2025cites this paper
• The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid‐Induced Fibrosis Mice

  2025cites this paper
• Tolerogenic Therapies in Cardiac Transplantation

  2025cites this paper
• Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation—A Transplant Nephrologist's Perspective

  2025cites this paper
• A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System(FAERS) Event for Belatacept.

  2025cites this paper
• Long‐Term Outcomes of Belatacept Versus Tacrolimus Following T‐Cell Depleting Induction in Adult Kidney Transplantation

  2025influential citation
• Tailoring of Immunosuppression With Belatacept in De Novo and Conversion Settings and Risk Mitigation Strategies.

  2025cites this paper
• Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period

  2025cites this paper
• Patterns of belatacept use and risk of post-transplant lymphoproliferative disorder in US kidney transplant recipients: An analysis of the Organ Procurement and Transplantation Network database

  2025cites this paper
• Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapy.

  2025cites this paper
• Belatacept and non-melanoma skin cancer risk in kidney transplant recipients: a narrative review from a mechanistic and clinical perspective

  2025cites this paper
• Exploring Costimulatory Blockade-Based Immunologic Strategies in Transplantation: Are They a Promising Immunomodulatory Approach for Organ and Vascularized Composite Allotransplantation?

  2024cites this paper
• Cancer Screening and Cancer Treatment in Kidney Transplant Recipients

  2024cites this paper
• Betreuung von Patienten nach Nierentransplantation

  2024cites this paper
• Approach to Late Noninfectious Post-Transplant Complications.

  2024cites this paper
• Belatacept based immunosuppression: What and when to combine?

  2024cites this paper
• Long-term Safety in Epstein–Barr Virus–Seropositive Kidney-only Transplant Recipients Treated With Belatacept in Clinical Practice: Final Study Results From the ENLiST Registry

  2024cites this paper
• Safety and Efficacy of Very Early Conversion to Belatacept in Pediatric Kidney Transplantation with Transplant-Associated Thrombotic Microangiopathy: Case Study and Review of Literature

  2024influential citation
• Calcineurin inhibition, cardiovascular consequences, vascular resistance, and potential responses

  2024cites this paper
• Non‐Redundant Roles of T Cell Costimulation Pathways in Inflammatory Arthritis Revealed by Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN‐101)

  2023cites this paper
• Minimizing Metabolic and Cardiac Risk Factors to Maximize Outcomes After Liver Transplantation

  2023cites this paper
• Preventing Rejection of the Kidney Transplant

  2023cites this paper
• Early conversion to belatacept-based immunosuppression regimen promotes improved long-term renal graft function in kidney transplant recipients.

  2023cites this paper
• Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction

  2023cites this paper
• Immunosuppression in HIV-positive kidney transplant recipients

  2023cites this paper
• Desensitization and belatacept-based maintenance therapy in pregnancy-sensitized monkeys receiving a kidney transplant

  2023cites this paper
• Conventional and Novel Approaches to Immunosuppression in Lung Transplantation.

  2023cites this paper
• Hypertension in kidney transplant recipients

  2022cites this paper
• Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens.

  2022cites this paper
• Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial

  2022cites this paper
• Preservation of Antiviral Immunologic Efficacy Without Alloimmunity After Switch to Belatacept in Calcineurin Inhibitor–Intolerant Patients

  2022cites this paper
• Consensus recommendations for use of maintenance immunosuppression in solid organ transplantation: Endorsed by the American College of Clinical Pharmacy, American Society of Transplantation, and the International Society for Heart and Lung Transplantation

  2022cites this paper
• Interventions Against Posttransplantation Diabetes: A Scientific Rationale for Treatment Hierarchy Based on Literature Review.

  2022cites this paper
• Harnessing the B Cell Response in Kidney Transplantation – Current State and Future Directions

  2022influential citation
• Induction Therapy and Therapeutic Antibodies.

  2022cites this paper
• Influence of Immunosuppressive Regimen on Diffusivity and Oxygenation of Kidney Transplants—Analysis of Functional MRI Data from the Randomized ZEUS Trial

  2022cites this paper
• New onset hypertension after transplantation

  2022cites this paper
• Calculated cardiovascular risk after conversion from calcineurin inhibitor to belatacept in kidney transplant recipients: A randomized controlled trial

  2022cites this paper
• Prevention of Post-Transplant Diabetes Mellitus: Towards a Personalized Approach

  2022cites this paper
• Risk of post‐transplant cardiovascular events in kidney transplant recipients with preexisting aortoiliac stenosis

  2021cites this paper
• Adverse Effects of Immunosuppression: Infections.

  2021cites this paper
• Effects of uremic toxins on hippocampal synaptic transmission: implication for neurodegeneration in chronic kidney disease

  2021cites this paper
• Post-transplant Recipient Infectious Challenges

  2021cites this paper
• Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders

  2021cites this paper
• Posttransplant Lymphoproliferative Disorder Following Kidney Transplantation: A Review.

  2021cites this paper
• Approach to the patient: Early post-renal transplant hyperglycemia

  2021cites this paper
• Optimal Immunosuppression Strategy in the Sensitized Kidney Transplant Recipient

  2021cites this paper
• Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials

  2021cites this paper
• Pregnancy care in solid organ transplant recipients

  2021cites this paper
• Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation

  2021cites this paper
• Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de novo renal transplantation in Elderly patients

  2021cites this paper
• Rôle des immunosuppresseurs dans le succès d’une greffe d’organe

  2021cites this paper
• Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

  2021cites this paper
• Ischemia-reperfusion injury

  2021cites this paper
• Update on Treatment of Hypertension After Renal Transplantation

  2021cites this paper
• Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus

  2021cites this paper
• Role of hypertension in kidney transplant recipients

  2021influential citation
• Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review

  2021cites this paper
• Pre‐transplant maintenance dialysis duration and outcomes after kidney transplantation: A multicenter population‐based cohort study

  2021cites this paper
• Novel management of diabetes in kidney transplantation

  2020cites this paper
• Glucose Metabolism After Kidney Transplantation: Insulin Release and Sensitivity With Tacrolimus- Versus Belatacept-Based Immunosuppression.

  2020cites this paper
• Post-Transplantation Diabetes Mellitus

  2020cites this paper
• Costimulation Blockade in Vascularized Composite Allotransplantation

  2020influential citation
• Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients

  2020cites this paper
• Management of post‐transplant diabetes: immunosuppression, early prevention, and novel antidiabetics

  2020cites this paper
• Review: Ischemia Reperfusion Injury—A Translational Perspective in Organ Transplantation

  2020cites this paper
• Costimulation Blockade in Kidney Transplant Recipients

  2019influential citation
• Non-immunological complications following kidney transplantation

  2019cites this paper
• Conversion from calcineurin inhibitors to belatacept in HLA- sensitized kidney-transplant recipients with low-level donor specific antibodies.

  2019cites this paper
• Infection with a virus generates a polyclonal immune response with broad alloreactive potential.

  2019cites this paper
• The role of B cell immunity in VCA graft rejection and acceptance.

  2019cites this paper
• Immunosenescence and Immunosuppressive Drugs in the Elderly

  2019cites this paper
• Secondary lymphoid tissue and costimulation‐blockade resistant rejection: A nonhuman primate renal transplant study

  2019cites this paper
• Arterial Stiffness in the Heart Disease of CKD.

  2019cites this paper
• Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience

  2019cites this paper
• Induction of immunological tolerance to myelinogenic glial-restricted progenitor allografts.

  2019cites this paper
• Effects of esomeprazole and pantoprazole on renal function in stable kidney transplantation recipients: A randomized clinical trial.

  2019cites this paper
• Belatacept in kidney transplantation and its limitations

  2019cites this paper
• Results of Renal Transplantation

  2019cites this paper
• Cancer in Dialysis and Transplant Patients

  2019cites this paper
• The Immunology of Transplantation

  2019cites this paper
• Late Conversion From Calcineurin Inhibitors to Belatacept in Kidney-Transplant Recipients Has a Significant Beneficial Impact on Glycemic Parameters

  2019cites this paper
• Tacrolimus

  2019cites this paper
• Post-transplantation diabetes in kidney transplant recipients: an update on management and prevention

  2018cites this paper
• Hypertension guidelines: How do they apply to kidney transplant recipients.

  2018cites this paper
• Improved Glucose Tolerance in a Kidney Transplant Recipient With Type 2 Diabetes Mellitus After Switching From Tacrolimus To Belatacept: A Case Report and Review of Potential Mechanisms

  2018influential citation
• Cardiovascular risk in renal transplant recipients

  2018cites this paper
• Immunsuppression beim nierentransplantierten Patienten über 65 Lebensjahre

  2018cites this paper
• Renal Transplant Immunosuppression in Patients With Hemolytic Uremic Syndrome: Four Case Reports.

  2018cites this paper
• Establishing a Core Outcome Measure for Graft Health: A Standardized Outcomes in Nephrology-Kidney Transplantation (SONG-Tx) Consensus Workshop Report

  2018cites this paper
• Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in de novo and recurrent diseases

  2018cites this paper
• Immunsuppression beim nierentransplantierten Patienten über 65 Lebensjahre

  2018cites this paper
• Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types

  2018cites this paper
• Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network

  2017cites this paper
• An Antigen-Presenting and Apoptosis-Inducing Polymer Microparticle Prolongs Alloskin Graft Survival by Selectively and Markedly Depleting Alloreactive CD8+ T Cells

  2017cites this paper
• Steroid withdrawal after renal transplantation: a retrospective cohort study

  2017cites this paper
• Two Decades of Tacrolimus in Renal Transplant: Basic Science and Clinical Evidences.

  2017cites this paper
• Maintenance immunosuppressants in the management of antibody-mediated renal allograft rejection: which regimen is best?

  2017cites this paper